Lisata Therapeutics, Inc. (LSTA) Earnings History
Annual and quarterly earnings data from 1994 to 2025
Loading earnings history...
LSTA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
LSTA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 14.1% | -10711.2% | -9756.5% |
| 2024 | 100.0% | -2240.9% | -1998.5% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export LSTA earnings history in CSV or JSON format
Free sign-in required to download data
Lisata Therapeutics, Inc. (LSTA) Earnings Overview
As of May 8, 2026, Lisata Therapeutics, Inc. (LSTA) reported trailing twelve-month net income of -$17M, reflecting +20.4% year-over-year growth. The company earned $-1.91 per diluted share over the past four quarters, with a net profit margin of -9756.5%.
Looking at the long-term picture, LSTA's historical earnings data spans multiple years. The company achieved its highest annual net income of $23M in fiscal 2017.
Lisata Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ADCT (-$137M net income, -175.3% margin), IMVT (-$464M net income), TPVG (-$12M net income, 50.6% margin), LSTA has room to improve margins relative to the peer group. Compare LSTA vs ADCT →
LSTA Earnings vs Peers
Earnings metrics vs comparable public companies
LSTA Historical Earnings Data (1994–2025)
31 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$17M | +17.0% | -$18M | $-1.91 | -9756.5% | -10711.2% |
| 2024 | -$20M | +4.1% | -$22M | $-2.40 | -1998.5% | -2240.9% |
| 2023 | -$21M | +61.6% | -$26M | $-2.58 | - | - |
| 2022 | -$54M | -97.4% | -$58M | $-10.47 | - | - |
| 2021 | -$27M | -237.0% | -$29M | $-7.45 | - | - |
| 2020 | -$8M | +59.5% | -$19M | $-7.91 | - | - |
| 2019 | -$20M | -24.3% | -$20M | $-29.20 | - | - |
| 2018 | -$16M | -170.4% | -$17M | $-25.03 | - | - |
| 2017 | $23M | +170.4% | -$28M | $38.43 | - | - |
| 2016 | -$33M | +59.6% | -$31M | $-74.81 | -92.6% | -88.8% |
See LSTA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LSTA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LSTA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLSTA — Frequently Asked Questions
Quick answers to the most common questions about buying LSTA stock.
Is LSTA growing earnings?
LSTA EPS is $-1.91, with earnings growth accelerating to +20.4%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-17M.
What are LSTA's profit margins?
Lisata Therapeutics, Inc. net margin is -9756.5%, with operating margin at -10711.2%. Below-average margins reflect competitive or cost pressures.
How consistent are LSTA's earnings?
LSTA earnings data spans 1994-2025. The accelerating earnings trend is +20.4% YoY. Historical data enables comparison across business cycles.